Table 5.

Results of sensitivity analysis of the duration of disutility related to surgical risk-reducing strategies

Strategy	Costs	QALYs	dCostsa	dQALYsb			ICER
	Duration of disutility for the surgical risk-reducing strategies
	Base case (for 1 year)				for 5 years	for 10 years
BRCA1
IS	141,293	14.48	Reference				Abs. dominated
CP	136,957	15.24	− 4336	0.76	(for 5 years)		Abs. dominated
PBM	115,802	17.28	− 25,491	2.80	2.43	2.05	Abs. dominated
PBSO	112,814	16.79	− 28,479	2.31	2.01	1.73	Abs. dominated
PBM & PBSO	76,639	19.24	− 64,654	4.76	4.10	3.40	Dominant
Brca2
IS	102,245	15.52	Reference				Abs. dominated
PBSO	97,091	16.85	− 5154	1.33	1.03	0.74	Abs. dominated
CP	78,478	17.58	− 23,767	2.07	(for 5 years)		Abs. dominated
PBM	70,562	19.24	− 31,683	3.73	3.34	2.93	Abs. dominated
PBM & PBSO	60,770	19.85	− 41,475	4.34	3.67	2.95	Dominant

^adCosts: average difference in costs per women who opted for prophylactic measures compared to intensified surveillance (reference)

^bdQALYs: average difference in QALYs per woman who opted for prophylactic measures compared to intensified surveillance (reference)

QALYs (quality-adjusted life years), ICER (incremental cost-effectiveness ratio), abs. (absolutely), IS (intensified surveillance), PBM (prophylactic bilateral mastectomy), PBSO (prophylactic bilateral salpingo-oophorectomy), CP (chemoprevention)